The use of paclitaxel coated balloon (PCB) in acute coronary syndrome of small vessel de novo lesions: an analysis of a prospective ‘real world’ registry

Ahmad Syadi Mahmood Zuhdi1*, Uwe Zeymer2, Matthias Waliszewski3, Martin Spiecker4, Muhammad Dzafir Ismail1, Michael Boxberger3, Marcus Ferrari5, Imran Zainal Abidin1 and Wan Azman Wan Ahmad1

Abstract
Background: Paclitaxel-coated balloon (PCB) angioplasty in small vessel de novo lesions has favourable outcome and appears to be an alternative to stent implantation. However there is limited data on its use specifically in small vessel acute coronary syndrome (ACS).

Methods: We analyse patients data from the SeQuent Please Small Vessel ‘PCB only’ Registry. It was an international, prospective, multicentre registry which enrolled patients with de novo lesions of small vessel diameter (≥2.0, ≤2.75 mm). Patients were divided into the ACS group and the non-ACS group and comparison made between the two groups. The primary end-point was clinically driven target lesion revascularisation (TLR) at 9 months. Secondary end-points were acute technical success, 30-day and 9-month major adverse cardiac events (death, myocardial infarction or TLR) (MACE) and the occurrence of definite lesion and vessel thrombosis.

Results: A total of 447 patients were enrolled for this registry of which 105 (23.5%) patients were ACS (STEMI and NSTEMI). The procedural success rate was 98.1% in ACS group. The mean vessel diameter for the ACS and non-ACS group were 2.15 ± 0.36 and 2.14 ± 0.35 respectively. Similar mean lesion length of around 15.5 mm was recorded in both groups. Additional stenting was required in 9.3% ACS and 6.5% non-ACS, p = 0.308. Reasons for additional stenting were target lesion related dissection (57.6%) or non-target lesion stenosis (41.2%). More than half of the patients had 4 weeks of aspirin/clopidogrel (57.1% ACS, 60.5% non-ACS). No significant difference between the ACS and non-ACS groups with regards to the duration and types of DAPT during follow up. At 30-day, MACE rate were (0% ACS vs 0.3% non-ACS, p = 0.599). At 9 months TLR rates were (1.2% ACS vs 4.3% non-ACS, p = 0.180) and MACE rates (3.6% ACS vs 5.0% non-ACS, p = 0.601).

Conclusion: PCB in ACS with small vessel de novo lesions has low 30-day and 9-month TLR/MACE rates comparable to non-ACS small vessels. Thus it appears to be an alternative to stent implantation in the treatment ACS.

Keywords: Paclitaxel, Balloon angioplasty, Small vessels, Acute coronary syndrome, MACE

Background
Paclitaxel coated balloon (PCB) angioplasty has proven benefit in the treatment of bare-metal and drug-eluting in-stent restenosis (ISR) (Scheller et al. 2006, 2008, 2012; Harbara et al. 2011; Byrne et al. 2013). The efficacy of PCB in treating small vessel de-novo lesions is also emerging with promising data so far (Ali et al. 2011; Zeymer et al. 2014). However, the data on PCB angioplasty specifically in acute coronary syndrome (ACS) is still lacking. Intravascular plaque rupture and thrombus formation in ACS
cast doubt on the effectiveness of paclitaxel drug to be adequately delivered to the vessel wall. However, the increased risk of in-stent thrombosis and restenosis in small vessel PCI with stents (Akiyama et al. 1998; Kasaoka et al. 1998) has made PCB angioplasty, which leaves no intravascular metal a good alternative in theory. Therefore we utilise patients data from a prospective ‘real world’ registry to determine the feasibility of PCB angioplasty in acute coronary syndrome of small vessel de-novo lesions by means of major adverse cardiac event (MACE) and target lesion revascularisation (TLR) at 30-day and 9 months follow up.

**Methods**

**Centres**
Prospective patients enrolment was done in Germany (20 centres), Malaysia (4 centres), Singapore (3 centres), Italy (2 centres), France (1 centre), Finland (1 centre), Poland (1 centre), China (1 centre) and Iran (1 centre). The study was approved by the individual institutional review boards of the participating centres.

**Materials**
In this registry the paclitaxel coated percutaneous transluminal coronary angioplasty (PTCA) catheter based on the Paccocath Technology (SeQuent Please, B. Braun Melsungen AG) was used.

**Inclusion and exclusion criteria**
Patients ≥ 18 years of age with de novo small vessel lesions (2.0–2.75 mm diameter) and stable angina, documented ischemia (non-ACS) and acute coronary syndrome (ACS) were recruited for this registry. There were no patient exclusion criteria except those associated with contraindications for anti-platelet therapy.

**Procedural approach**
It was the purpose of this registry to treat de novo lesions with the PCB catheter only without additional stent implantations, according to the German Consensus Group recommendations (Kleber et al. 2011). Predilatation with an uncoated balloon catheter according to the above mentioned recommendation was mandatory (Kleber et al. 2011). In cases of severe dissections or unsatisfactory results post-PCB, the implantation of a BMS was recommended and left to the discretion of the interventionalist. Vascular access was from the femoral or radial route with recommended diagnostic catheter of at least 5 French in diameter. Due to the ‘all-comers’ nature of this registry, efforts were made to not interfere with established national co-medication recommendations. Dual anti-platelet therapy (DAPT) with acetylsalicylic acid (aspirin) and an ADP receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) was recommended, but at the discretion of the treating physician. An injectable anticoagulant was advised on the basis of local routines in the participating catheterisation laboratories.

**Postprocedural medication**
An ADP receptor antagonist (clopidogrel 75 mg/day, prasugrel 10 mg/day or ticagrelor 180 mg/day) was recommended for either 1, 3–6 or 12 months together with aspirin 100–325 mg/day at the discretion of the treating physician.

**Definitions**
MACE included TLR, myocardial revascularisation, and death of cardiac or unknown origin. MI was diagnosed with corresponding ECG changes and/or cardiac enzyme elevations according to each institution’s routine diagnostic algorithms.

**End points**
Clinically driven TLR (either by re-do PCI or CABG) at 9 months post procedure was the primary end point. Secondary end points were procedural success rate, definite acute/sub-acute vessel thrombosis rates based on the Academic Research Consortium (ARC) criteria (Cutlip et al. 2007) and major adverse cardiac events (MACE) as the composite of TLR, cardiac death, and myocardial infarction.

**Data collection**
Baseline and clinical follow-up data were collected through a web based data acquisition system between June 2011 and December 2012. Follow up data were typically collected during routine visits with the treating physician. National principal investigators (one per country) were responsible for the accuracy of their datasets. Source data verification was done when the routinely performed web based plausibility checks indicated discrepancies.

**Statistical analysis**
Categorical variables were evaluated with the $\chi^2$ test. Continuous variables were typically compared with the unpaired two-tailed Student’s t test. In parameters with Gaussian distributions, samples were described using the mean and the SD. SPSS V.20.0 (IBM, Munich, Germany) was used for all analyses at a significance level $\alpha$ of 0.05.

**Results**

**Patients demographics and presentation**
A total of 471 PCB angioplasties were performed in 447 patients of which 113 (25 %) were ACS (STEMI/ NSTEMI). A small proportion of patients (7.2 %) had bail-out BMS stenting. Patients baseline characteristics
are shown in Table 1. All clinical characteristics were similar in the ACS and non-ACS groups except for hyperlipidaemia and previous PCI where the non-ACS group had higher rates for both.

**Lesion characteristics and procedural data**
The mean vessel diameter for the ACS and non-ACS group were 2.15 ± 0.36 and 2.14 ± 0.35 respectively. Similar mean lesion length of around 15.5 mm was recorded in both groups. The LAD was the most common target vessel for both the ACS and non-ACS group. The distribution of coronary arteries treated were similar for both groups. In terms of lesion characteristics, the ACS group had more acute total occlusion (15.1 vs 7.4 %, p = 0.015) and higher thrombus burden rate (13.2 vs 0.3 %, p = 0.001). The degree of stenosis is also higher in the ACS group (88.5 vs 84.5 %, p = 0.001). Apart from the above, both ACS and non-ACS group have no significant difference in coronary artery complexity. Additional stenting was required in 9.3 % ACS and 6.5 % non-ACS, p = 0.308. Reasons for additional stenting were target lesion related dissection (57.6 %) or non-target lesion stenosis (41.2 %).

**Periprocedure anti-platelet therapy**
All patients were on aspirin. Clopidogrel was the most common second anti-platelet drug followed by prasugrel, ticagrelor and ticlopidine. A small minority of patients had more acute total occlusion (5.7 % ACS and 4.7 % non-ACS). No significant difference in the ACS and non-ACS groups in terms of periprocedural anti-platelet therapy (Tables 2, 3, 4).

**Duration of dual anti-platelet therapy (DAPT) during follow up**
More than half of the patients had 4 weeks of aspirin/clopidogrel (57.1 % ACS, 60.5 % non-ACS). No significant difference between the ACS and non-ACS groups with regards to the duration and types of DAPT during follow up.

**Clinical outcome**
Table 5 illustrates the clinical outcome of the patients. The primary end-point of 9 months TLR were 1.2 % ACS versus 4.3 % non-ACS (p = 0.180). Overall, the MACE rate at 9 months was 4.7 % for the entire registry. MACE rates were 0 % at 30-day and 3.6 % at 9 months in the ACS group. The rates were lower as compared to the non-ACS group, but were not significantly different. No cases of target lesion/vessel or non-target vessel thrombosis reported in the ACS group.

**Discussion**
The definition of small vessel from the literature varies. For our registry, we took the cut-off point of 2.75 mm or less as small vessel. From coronary revascularisation point of view, small vessel PCIs make up a significant portion constituting to about 35–45 % of all PCIs (Zeymer and Scheller 2011). PCI with stenting in small vessels remains challenging as the outcome is poorer compared to PCI of larger vessels. Small vessels have less tolerance to neointimal proliferation post stent implantation (Hausleiter et al. 2002; Agostoni et al. 2005). The risk of ISR in small vessels even with the introduction of DES stents is still considered significant (Meier et al. 2006; Togni et al. 2007). This is in addition to the already known complication of stent thrombosis.

PCB angioplasty in small vessels was first reported in 2010 which showed a TLR rate of 4.9 % in PCB only patients (n = 73) with reference diameter of 2.36 ± 0.18 mm and lesion lengths of 11.3 ± 4.3 mm (Unverdoben et al. 2010). After the initial failure of PIC-COLETTO study trial (Cortese et al. 2010) to show a non-inferiority of PCB versus DES, came a larger randomised trial comparing PCB and DES in small vessel de novo lesions (BELLO study) (Latib et al. 2012). BELLO study comprising 182 patients, showed superiority of PCB over TAXUS stents in terms of late lumen loss (LLL) and similar angiographic restenosis, target lesion revascularisation and MACE rates at 6 months. Patients from the BELLO study were then followed up for 2 years and showed better TLR rates (compared to PES TAXUS) at these values.
Stent implantation is considered the standard and well established treatment for ACS (Windecker et al. 2014) to improve clinical outcome. However PCI in ACS in small vessels is not spared from the issue of high ISR rate and stent thrombosis. Evidence of PCB specifically in ACS is still sparse. Besic et al. (2015) reported a significantly lower LLL of PCB + BMS combination compared to BMS alone at 6 months but no significant difference in MACE and binary LLL and ISR were noted.

There is now rather convincing data on the efficacy and safety of PCB in small vessels de novo lesions in general (Zeymer et al. 2014). However its use in ACS in 6 months (4.4 vs 7.6 %), 1 year (6.7 vs 12.1 %) and 2 years (6.8 vs 12.1 %) (Naganuma et al. 2015).

Table 2: Lesion characteristics and procedural data in ACS and non-ACS patients

| Variable                        | All patients | Non ACS | ACS | p value |
|---------------------------------|--------------|---------|-----|---------|
| Number of lesions               | 471          | 353     | 118 | –       |
| Target vessel                   |              |         |     |         |
| LAD                             | 193 (41.0 %) | 154 (42.2 %) | 39 (36.8 %) | 0.128 |
| LCX                             | 126 (26.8 %) | 91 (24.9 %)  | 35 (33.0 %)  |       |
| RCA                             | 94 (20.0 %)  | 69 (18.9 %)  | 25 (23.6 %)  |       |
| Ramus intermedius              | 19 (4.0 %)   | 17 (4.7 %)   | 2 (1.9 %)    |       |
| Other                           | 39 (8.9 %)   | 34 (9.3 %)   | 5 (4.7 %)    |       |
| Lesion characteristics          |              |         |     |         |
| Total occlusion                 | 43 (9.1 %)   | 27 (7.4 %)   | 16 (15.1 %)  | 0.015 |
| Chronic total occlusion         | 16 (3.4 %)   | 13 (3.6 %)   | 3 (2.8 %)    | 0.714 |
| Thrombus burden                 | 15 (3.2 %)   | 1 (0.3 %)    | 14 (13.2 %)  | <0.001|
| Diffuse vessel disease          | 200 (57.5 %) | 156 (42.7 %) | 44 (41.5 %)  | 0.822 |
| Calcification                   | 112 (33.8 %) | 83 (22.7 %)  | 29 (27.4 %)  | 0.325 |
| Vein graft                      | 9 (1.9 %)    | 8 (2.2 %)    | 1 (0.9 %)    | 0.409 |
| Ostial lesion                   | 48 (10.2 %)  | 35 (9.6 %)   | 13 (12.3 %)  | 0.423 |
| Bifurcation lesion              | 45 (9.6 %)   | 35 (9.6 %)   | 10 (9.4 %)   | 0.962 |
| Severe tortuosity               | 45 (9.6 %)   | 32 (8.8 %)   | 13 (12.3 %)  | 0.281 |
| AHA/ACC type B2/C lesion        | 182 (38.6 %) | 133 (36.4 %) | 49 (46.2 %)  | 0.068 |
| Reference diameter (mm)         | 2.14 ± 0.35  | 2.14 ± 0.35  | 2.15 ± 0.36  | 0.973 |
| Lesion length                   | 15.5 ± 7.0   | 15.5 ± 7.3   | 15.6 ± 5.9   | 0.926 |
| Degree of stenosis (%)          | 85.3 ± 11.2  | 84.5 ± 11.4  | 88.5 ± 10.2  | 0.001 |
| Procedural data                 |              |         |     |         |
| Predilation device diameter (mm)| 2.02 ± 0.25  | 2.01 ± 0.24  | 2.04 ± 0.29  | 0.303 |
| Predilation device length (mm)  | 15.6 ± 4.5   | 15.7 ± 4.6   | 15.5 ± 4.3   | 0.655 |
| Predilation device pressure (atm)| 11.8 ± 3.1   | 11.8 ± 3.2   | 11.7 ± 3.1   | 0.941 |
| DEBs used                       | 478          | 371       | 107   | –       |
| DEBs per patient                | 1.07 ± 0.29  | 1.08 ± 0.32  | 1.03 ± 0.17  | 0.114 |
| DEB diameter (mm)               | 2.33 ± 0.31  | 2.32 ± 0.30  | 2.37 ± 0.32  | 0.138 |
| DEB length (mm)                 | 19.2 ± 4.5   | 19.2 ± 4.5   | 18.8 ± 4.3   | 0.425 |
| DEB inflation pressure (atm)    | 110 ± 3.4    | 109 ± 2.8    | 113 ± 4.9    | 0.352 |
| DEB inflation time (s)          | 48.5 ± 15.9  | 48.5 ± 16.0  | 48.6 ± 15.6  | 0.982 |
| Additional stent                | 34 (7.2 %)   | 24 (6.5 %)   | 10 (9.3 %)   | 0.308 |
| Overall technical success per used device (n = 478) | 473 (99.0 %) | 368 (99.2 %) | 105 (98.1 %) | 0.342 |

LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, AHA/ACC American Heart Association/American College of Cardiology, DEB drug eluting balloon

Table 3: Peri-procedural antiplatelet therapy in ACS and non-ACS patients

| Variable                        | All patients | Non ACS | ACS | p value |
|---------------------------------|--------------|---------|-----|---------|
| Aspirin                         | 447 (100 %)  | 334 (100 %) | 113 (100 %) | –       |
| Clopidogrel                     | 364 (81.4 %) | 277 (81.0 %) | 87 (82.9 %) | 0.792   |
| Prasugrel                       | 41 (9.2 %)   | 32 (9.4 %)  | 9 (8.6 %)   |         |
| Ticagrelor                      | 8 (1.8 %)    | 6 (1.8 %)   | 2 (1.9 %)   |         |
| Ticlopidine                     | 4 (0.9 %)    | 4 (1.2 %)   | 0 (0.0 %)   |         |
| Aspirin + vitamin K antagonists | 9 (2.0 %)    | 8 (2.3 %)   | 1 (1.0 %)   |         |
| Aspirin only                    | 21 (4.7 %)   | 15 (4.4 %)  | 6 (5.7 %)   |         |
| GP IIb/IIIa inhibitors          | 10 (2.2 %)   | 8 (2.3 %)   | 2 (1.9 %)   | 0.792   |

GP IIb/IIIa glycoprotein IIb/IIIa
particular is still unclear. Ho et al. (2015) reported MACE rate of 4.5 % in PCB primary angioplasty of STEMI at 30-day follow up. Our study shows the outcome of PCB in ACS and non-ACS is comparably similar in small vessel de novo lesions. MACE rate at 30-days and 9-months follow up showed a better trend in ACS than the non-ACS group. MACE at 30 days is 0.3 % non-ACS versus 0 % ACS and 9-months MACE is 5.0 % non-ACS versus 3.6 % ACS. In comparison to other small vessel de novo lesion studies, TLR at 9-months follow up was reported as 3.6 % (PCB only) and 4.0 % (PCB + BMS) (Zeymer et al. 2014) and 1 % (PCB only) and 2.4 % (PCB + BMS) (Wohrle et al. 2012). The mean vessel diameter difference for the two above studies might explain the lower rate of TLR.

### Conclusion

The use of PCB in ACS of small vessel de novo lesion is associated with a low TLR/MACE rate comparable to small vessel PCB angioplasty in general. This suggests PCB angioplasty in ACS is a feasible alternative to stent implantation in ACS.

### Study limitation

Since the purpose of this observational study was the documentation of PCB angioplasty in the clinical routine, event underreporting may have occurred. In this context, the procedural details could have been specified in more detail as well. For instance in case of thrombus burden the type of the aspiration device would have been highly desirable. Furthermore, in the case of PCB angioplasty one needs to point out that the learning curve to treat small lesions with PCB only requires positive clinical feedback of each investigator. This entails a learning curve to accept angiographically ‘unpleasing’ results for the benefit of having no implant in a small vessel. However, due to the level of each investigator’s experience a selection bias could not be ruled out in this assessment.

### Authors’ contributions

Manuscript preparation and main idea: ASMZ. Principal site investigator for the registry: UZ, MS, MF. Data organisation and statistical analysis: MW, MB. Manuscript write up: MDI, IZA. Scientific and academic review of the manuscript: WAWA. All authors read and approved the final manuscript.

### Table 4 Duration of dual antiplatelet therapy during follow-up in ACS and non-ACS patients

| Variable                        | All patients | Non ACS | ACS | p value |
|---------------------------------|--------------|---------|-----|---------|
| Number of patients              | 447          | 334     | 113 | –       |
| 4 weeks aspirin 100 mg + clopidogrel | 267 (59.7 %) | 207 (60.5 %) | 60 (57.1 %) | 0.385 |
| 3 months aspirin 100 mg + clopidogrel | 5 (1.2 %)    | 5 (1.5 %) | 0 (0.0 %) |    |
| 6–12 months aspirin 100 mg + clopidogrel | 68 (15.2 %) | 52 (15.2 %) | 16 (15.2 %) |    |
| 12 months aspirin 100 mg + clopidogrel | 70 (15.7 %) | 47 (13.7 %) | 23 (21.9 %) |    |
| Aspirin 100 mg + clopidogrel life long | 2 (0.4 %)    | 2 (0.6 %) | 0 (0.0 %) |    |
| 12 months aspirin 100 mg + prasugrel | 3 (0.7 %)    | 2 (0.6 %) | 1 (1.0 %) |    |
| 12 months aspirin 100 mg + ticagrelor | 3 (0.7 %)    | 2 (0.6 %) | 1 (1.0 %) |    |
| Unknown                         | 29 (6.5 %)   | 24 (7.0 %) | 5 (4.8 %) |    |

### Table 5 Clinical outcomes in patient populations in ACS and non-ACS patients

| Variable                        | All patients | Non ACS | ACS | p value |
|---------------------------------|--------------|---------|-----|---------|
| Number of patients              | 447          | 334     | 113 | –       |
| Patients with clinical follow-up| 384 (85.9 %) | 301 (90.3 %) | 83 (73.5 %) | 0.021 |
| Follow-up time (months)         | 9.4 ± 1.7    | 9.5 ± 1.7 | 9.4 ± 1.6 | 0.875 |
| 30-day MACE                     | 1 (0.3 %)    | 1 (0.3 %) | 0 (0.0 %) | 0.599 |
| 30-day TLR                      | 1 (0.3 %)    | 1 (0.3 %) | 0 (0.0 %) | 0.599 |
| 30-day MI                       | 1 (0.3 %)    | 1 (0.3 %) | 0 (0.0 %) | 0.599 |
| 30-day cardiac death            | 0 (0.0 %)    | 0 (0.0 %) | 0 (0.0 %) | – |
| 9-month MACE                    | 18 (4.7 %)   | 15 (5.0 %) | 3 (3.6 %) | 0.601 |
| 9-month TLR                     | 14 (3.6 %)   | 13 (4.3 %) | 1 (1.2 %) | 0.180 |
| 9-month MI                      | 7 (1.8 %)    | 4 (1.3 %) | 3 (3.6 %) | 0.168 |
| 9-month cardiac death           | 0 (0.0 %)    | 0 (0.0 %) | 0 (0.0 %) | – |
| 9-month vessel thrombosis       | 3 (0.8 %)    | 3 (1.1 %) | 0 (0.0 %) | 0.356 |
| Target lesion                   | 0 (0.0 %)    | 0 (0.0 %) | 0 (0.0 %) | – |
| Target vessel                   | 2 (0.5 %)    | 2 (0.7 %) | 0 (0.0 %) | 0.457 |
| Non-target vessel               | 1 (0.3 %)    | 1 (0.3 %) | 0 (0.0 %) | 0.599 |

**MACE** major adverse cardiac events, **TLR** target lesion revascularisation, **MI** myocardial infarction

Acknowledgements

We thank Denny Herberger (Medical Scientific Affairs, B. Braun Vascular Systems) for his valuable logistic support.
Competing interests
Dr. Matthias Waliszewski and Dr. Michael Boxberger are from the B. Braun's Medical Scientific Affairs, Berlin Germany.

Consent
Written informed consent was obtained from the patients for publication of this manuscript. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Received: 26 January 2016   Accepted: 16 March 2016
Published online: 25 March 2016

References
Agostoni P, Biondi-Zoccai GGL, Gasparini GL, Anselmi M, Morando G, Turri M et al (2005) Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J 26:881–889
Akiyama T, Moussa I, Reimers B (1998) Angiographic and clinical outcome following coronary stenting of small vessels a comparison with coronary stenting of large vessels. J Am Coll Cardiol 32:1610–1618
Ali RM, Degenhardt R, Bhumki M, Bhumki S, Bhumki G et al (2016) Sirolimus-eluting balloon angioplasty: A systematic review. Interact Cardiovasc Thorac Surg 23:503–508
Bax JJ, D’Ancona M, Muster K, Napel S et al (2012) Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents. J Am Coll Cardiol 60:2473–2480
Byrne RA, Neumann J, Mehilli J, Pinieck S, Wolff B, Tiroch K et al (2013) Paclitaxel eluting balloons, paclitaxel eluting stents and balloon angioplasty in patients with non-ST elevation acute coronary syndrome. J Cardiol 381:461–467
Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S et al (2010) PICCOLETO Study prospective randomised clinical trial. The stent during PCI of small coronary vessels, a paclitaxel-coated balloon versus drug eluting. Heart 96:1291–1296
Kasaoka A, Tebis JM, Akiyama T (1998) Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol 32:1630–1635
Kleber FX, Marhey DG, Rittger H, Scheller B, German Drug-eluting Balloon Consensus Group (2011) How to use the drug-eluting balloon: recommendations by the German consensus group. Eurointervention 7(suppl K):K125-8
Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F et al (2012) A randomised multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss optimization) study. J Am Coll Cardiol 60:2473–2480
Meier B, Sousa E, Guagliumi G, Van den Branden F, Grenadier E, Windecker S et al (2006) Sirolimus eluting stents in small vessels. Am Heart J 151:1019
Naganuma T, Latib A, Squegilia GA, Mennozzi A, Castriota F, Micari A et al (2015) A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO study. Int J Cardiol 184:17–21
Scheller B, Herleim C, Bocksch W et al (2006) Treatment of in-stent restenosis with a paclitaxel-coated balloon catheter. N Eng J Med 355:2113–2124
Scheller B, Herleim C, Bocksch W, Rutsch W, Haghi D, Dietz U et al (2008) Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 97:773–781
Scheller B, Clever Y, Kelsch B, Herleim C, Bocksch W, Rutsch W et al (2012) Long term follow up after treatment of in-stent restenosis with a paclitaxel-coated balloon catheter. J Am Coll Cardiol Intv 5(3):323–330
Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S et al (2007) Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents. J Am Coll Cardiol 50:1123–1131
Unverdoven M, Kleber FX, Heuer H, Figulla HR, Vallbrach C, Leschke M et al (2010) Treatment of small coronary arteries with a paclitaxel balloon catheter. Clin Res Cardiol 99(5):165–174
Windecker S, Kohl P, Alfonsko F, Coller JP, Cremer J et al (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619
Wohrle J, Zadura M, Mobius-Winkler S, Leschke M, Opitz C, Ahmed W et al (2012) SeQuent please world wide registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol 60:1733–1738
Zeymer U, Scheller B (2011) PCI in small vessels: the case for a drug-coated balloon based intervention. Eurointervention 7(suppl K):K57–K60
Zeymer U, Waliszewski M, Speckler M, Gastmann O, Ferrari B, Ferrari M et al (2014) Prospective real world registry for the use of PCB only strategy in small vessel de novo lesions. Heart 100:311–316